NPHLA Daily
NPHLA Daily
Tuesday, October 6, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 9 trial updates
NPHLA tracked 9 new official records on this desk today: 9 trial updates. First: New trial registered: GLP1-SARCO (GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes)
Metabolic signal
New trial registered: PIVOT (Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access)
Phase 4, Kristin Clemens. Conditions: Obesity; Chronic Kidney Disease; Chronic Renal Disease; CKD. Interventions: Semaglutide; Virtual Weight Management Coaching. Investigational: trial-stage therapies are not approved for the use studied.
Regulatory signal
What changed today in Regulatory: 1 recall record, 1 safety alert
NPHLA tracked 2 new official records on this desk today: 1 recall record, 1 safety alert. First: Recall: Flowers Foods Issues Recall of Nature’s Own Hawaiian Bread Due to Undeclared Milk — reason given: not stated (firm: not stated).
AI & Technology signal
What changed today in AI & Technology: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in JMIR research protocols: “Evaluation of Ambient Voice Technology in the National Health Service in England: Protocol for a Phase 2 Study”.
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 9 trial updates
- What changed today in Regulatory: 1 recall record, 1 safety alert
- What changed today in AI & Technology: 1 new study
- New trial registered: PIVOT (Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access) (ClinicalTrials.gov (U.S. National Library of Medicine))
- New trial registered: Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) (ClinicalTrials.gov (U.S. National Library of Medicine))
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.